Hydration and N-acetylcysteine in acute renal failure caused by iodinated contrast medium: An experiment with rats

Journal of Nephrology

Volumn 21, Issue 5, 2008, Pages 783-788

  Pinto, Carolina F ^a,b   Watanabe, Mirian ^a   Vattimo, Maria de Fátima F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Acute renal failure; Contrast; N Acetylcysteine; Nephrotoxicity; Rats

Indexed keywords

ACETYLCYSTEINE; IODINATED CONTRAST MEDIUM; MEGLUMINE; PEROXIDE; SODIUM CHLORIDE; SODIUM IOTHALAMATE MEGLUMINE; UNCLASSIFIED DRUG; WATER; CONTRAST MEDIUM; CREATININE; MEGLUMINE IOTALAMATE; SCAVENGER;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; INTERMETHOD COMPARISON; KIDNEY FUNCTION; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; RAT; RENAL PROTECTION; URINE FLOW RATE; WATER TREATMENT; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FLUID THERAPY; KIDNEY; MALE; METABOLISM; PATHOLOGY; URINE; WISTAR RAT;

ACETYLCYSTEINE; ANIMALS; CONTRAST MEDIA; CREATININE; FLUID THERAPY; FREE RADICAL SCAVENGERS; IOTHALAMATE MEGLUMINE; KIDNEY; KIDNEY FAILURE, ACUTE; MALE; PEROXIDES; RATS; RATS, WISTAR;

EID: 63249084879     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Finn WF. The clinical and renal consequences of contrast-induced nephropathy. Nephrol Dial Transplant. 2006;21:i2-10.
2. Pannu N, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006;295:2765-2779.
3. Santos OF, Boim MA, Laranja SM, Schor N. Contrast medium-induced nephropathy. In: Massry SG, Glassock RJ, eds. Massry and Glassock's textbook of nephrology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
4. McCullough PA, Adam A, Becker CR, et al; CIN Consensus Working Panel. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006;98:5K-13K. Epub 2006 Feb 10.
5. Briguori C, Tavano D, Colombo A. Contrast agent-associated nephrotoxicity. Prog Cardiovasc Dis. 2003;45:493-503.
6. Cox CD, Tsikouris JP. Preventing contrast nephropathy: what is the best strategy? A review of the literature. J Clin Pharmacol. 2004;44:327-337.
7. Tepel M, Zidek W. N-Acetylcysteine in nephrology: contrast nephropathy and beyond. Curr Opin Nephrol Hypertens. 2004;13:649-654.
8. Laranja SMR, Schor N. Nefrotoxidade por contraste radiológicos. In: Schor N, Boim MA, Santos OP, eds. Insuficiẽncia Renal Aguda. 1st Ed. São Paulo: Sarvier; 1997:129-132.
9. Burdmann EA, Vieira Junior JM, Vidal EC. Princípios de nefrologia e distúrbios hidroeletrolíticos. In: Nefropatia tóxica e tubulointersticial: nefrotoxicidade do meio de contraste radiológico. Rio de Janeiro: Guanabara Koogan; 1996:325-332.
10. Yao K, Heyne N, Erley CM, Risler T, Osswald H. The selective adenosine A1 receptor antagonist KW-3902 prevents radiocontrast media-induced nephropathy in rats with chronic nitric oxide deficiency. Eur J Pharmacol. 2001;414:99-104.
11. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343;180-183.
12. Haeussler U, Riedel M, Keller F. Free reactive oxygen species and nephrotoxicity of contrast agents. Kidney Blood Press Res. 2004;27:167-171.
13. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773-2782.
14. Goldenberg I, Schechter M, Shlomi M, et al. Oral acetylcysteine as an adjunct to saline hydratation for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature. Eur Heart J. 2004;25:212-218.
15. Meine TJ, Washam J. N-acetylcysteine to prevent contrast nephropathy. Am Heart J. 2004;147:440-441.
16. Conesa EL, Valero F, Nadal JC, et al. N-Acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. Am J Physiol Regul Integr Comp Physiol. 2001;281:R730-R737.
17. Erley CM, Heyne N, Rossmeier S, Vogel T, Risler T, Oswald H. Adenosine and extracellular volume in radiocontrast media-induced nephropathy. Kidney Int. 1998;54(Suppl 67):S192-S194.
18. Idée JM, Lancelot E, Pines E, Corot C. Prophylaxis of iodinated contrast media-induced nephropathy: a pharmacological point of view. Invest Radiol. 2004;39:155-170.
19. Asif A, Epstein M. Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 2004;44:12-24.
20. Katholi RE, Woods WT, Taylor GJ, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998;32:64-71.
21. Granger DN, Hollworth ME, Parks DA. Ischemia-reperfusion urgency: role for oxygen-derived free radicals. Acta Physiol Scand. 1986;126(Suppl 548):47-63.
22. Rehan A, Johnson KJ, Kunkel RG, Wiggins RC. Role of oxygen radicals in phorbol myristate acetate-induced glomerular injury. Kidney Int. 1985;27:503-511.
23. Yenicerioglu Y, Yilmaz O, Sarioglu S, et al. Effects of Nacethylcysteine on radiocontrast nephropathy in rats. Scand J Urol Nephrol. 2006;40:63-69.
24. Lee HT, Jan M, Bae SC, et al. A1 adenosine receptor knockout mice are protected against acute radiocontrast nephropathy in vivo. Am J Physiol Renal Physiol. 2006;290:F1367-F1375.
25. Gay C, Collins J, Gebicki M. Hydroperoxide assay with the ferric-xylenol orange complex. Anal Biochem. 1999;273:149-155.
26. Junqueira LC, Carneiro J. Histologia básica: métodos de estudo. Rio de Janeiro: Guanabara; 1990.
27. Long LH, Enas PJ, Halliwell B. Hydrogen peroxide in human urine: implications for antioxidant defense and redox regulation. Biochem Biophys Res Commun. 1999;262:605-609.
28. Wang XJ, Mia YF, Chen KM, Morcos SK. Radiographic contrast media induced nephropathy: experimental observations and the protective of calcium blockers. Br J Radiol. 2001;74:1103-1108.
29. Vaziri N, Dicus M, Ho N, Rad-Boroujerdi L, Sindhu K. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int. 2003;63:179-185.
30. McCullough PA, Adam A, Becker CR, et al; CIN Consensus Working Panel. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006;98:27k-36k. Epub 2006 Feb 23.
31. Singh D, Kaur R, Chander V, Chopra K. Antioxidants in the prevention of renal disease. J Med Food. 2006;9:443-450.
32. Ishikawa I, Kiyanna S, Yoshiota T. Renal oxidants enzymes: their regulation and function. Kidney Int. 1994;45:1-9.
33. Martin-Mateo MC, Sanches-Portugal M, Iglesias S, de Paula A, Bustamante J. Oxidative stress in chronic renal failure. Ren Fail. 1999;21:155-167.
34. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest. 2001;107:7-11.
35. Massy ZA, Guijaro C, O'Donnel MP, et al. The central role of nuclear factor- B in mesangial cell activation. Kidney Int Suppl. 1999;71:S76-S79.
36. Wu M, Pritchard KA Jr, Kaminski PM, Fayngersh RP, Hintze TH, Wolin MS. Involvement of nitric oxide and nitrosolthiols in relaxation of pulmonary arteries to peroxynitrite. Am J Physiol. 1994;266:H2108-H2113.
37. Wu JM, Wang ZR, Hiseh TC, Bruder JL, Zou JG, Huang YZ. Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine. Int J Mol Med. 2001;8:3-17.
38. Erley C. Does hydration prevent radiocontrast-induced acute renal failure? Nephrol Dial Transplant. 1999;14:1064-1068.
39. Chertow GM. Prevention of radiocontrast nephropathy. JAMA. 2004;291:2376-2377.
40. Barrett BJ, Parfrey PS. Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med. 1994;331:1449-1450.